Mark C. Schneyer Sells 3,503 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Stock

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) CFO Mark C. Schneyer sold 3,503 shares of the stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $16.94, for a total transaction of $59,340.82. Following the transaction, the chief financial officer now directly owns 32,053 shares of the company’s stock, valued at approximately $542,977.82. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

ACADIA Pharmaceuticals Trading Down 0.2 %

NASDAQ:ACAD opened at $17.05 on Monday. The company has a market cap of $2.82 billion, a price-to-earnings ratio of -44.87 and a beta of 0.42. ACADIA Pharmaceuticals Inc. has a twelve month low of $16.16 and a twelve month high of $33.99. The stock has a fifty day simple moving average of $19.15 and a 200-day simple moving average of $23.33.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last announced its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported $0.28 earnings per share for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.04). The company had revenue of $231.04 million for the quarter, compared to the consensus estimate of $223.79 million. ACADIA Pharmaceuticals had a negative net margin of 8.44% and a negative return on equity of 15.67%. The company’s quarterly revenue was up 69.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.26) EPS. As a group, equities research analysts predict that ACADIA Pharmaceuticals Inc. will post 0.62 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. Needham & Company LLC reissued a “buy” rating and set a $32.00 price target on shares of ACADIA Pharmaceuticals in a research note on Tuesday, April 9th. Cantor Fitzgerald reiterated an “overweight” rating and set a $37.00 target price on shares of ACADIA Pharmaceuticals in a research report on Tuesday, April 30th. HC Wainwright restated a “buy” rating and issued a $33.00 price target on shares of ACADIA Pharmaceuticals in a research report on Wednesday, February 28th. TheStreet upgraded shares of ACADIA Pharmaceuticals from a “d” rating to a “c” rating in a research report on Tuesday, February 27th. Finally, StockNews.com raised shares of ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, January 30th. Three equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $32.13.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Empire Life Investments Inc. increased its holdings in shares of ACADIA Pharmaceuticals by 0.3% in the 4th quarter. Empire Life Investments Inc. now owns 174,815 shares of the biopharmaceutical company’s stock valued at $5,473,000 after acquiring an additional 467 shares during the period. Handelsbanken Fonder AB raised its position in shares of ACADIA Pharmaceuticals by 2.3% in the 4th quarter. Handelsbanken Fonder AB now owns 31,633 shares of the biopharmaceutical company’s stock valued at $990,000 after purchasing an additional 700 shares during the last quarter. Franklin Resources Inc. boosted its stake in ACADIA Pharmaceuticals by 1.6% in the 4th quarter. Franklin Resources Inc. now owns 50,405 shares of the biopharmaceutical company’s stock worth $1,578,000 after purchasing an additional 803 shares in the last quarter. Quest Partners LLC purchased a new stake in ACADIA Pharmaceuticals during the 4th quarter worth approximately $39,000. Finally, Phocas Financial Corp. increased its stake in ACADIA Pharmaceuticals by 1.9% during the 4th quarter. Phocas Financial Corp. now owns 66,957 shares of the biopharmaceutical company’s stock valued at $2,096,000 after purchasing an additional 1,266 shares in the last quarter. Institutional investors own 96.71% of the company’s stock.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.